SCHEMBL17709397

SCHEMBL17709397

COC(=O)Oc1ccc(-c2ccccc2)cc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
SLC6A9 P48067 2/20 0.50
EGFR P00533 2/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 1/20 0.45
BACE1 P56817 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
ACLY P53396 3/20 0.43
HDAC1 Q13547 2/20 0.43
APOBEC3A P31941 1/20 0.43
GFER P55789 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
APAF1 O14727 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17697650 0.90 SLC6A9 (0.51) SLC6A9EGFRMEN1KMT2AMAPT
SCHEMBL17720767 0.87 EGFR (0.55) KDM4ESLC6A9EGFRHPGDHSD17B10
SCHEMBL28530768 0.84 PTGDR2 (0.58) KDM4ESLC6A9HPGDHSD17B10MEN1
SCHEMBL25257345 0.84 SLC6A9 (0.47) KDM4ESLC6A9EGFRMEN1KMT2A
SCHEMBL10429619 0.83 BACE1 (0.61) KDM4ESLC6A9EGFRHPGDHSD17B10
SCHEMBL1834873 0.83 KDM4E (0.61) KDM4EHPGDHSD17B10MEN1KMT2A
SCHEMBL17697651 0.83 SLC6A9 (0.51) SLC6A9EGFRMEN1KMT2AMAPT
SCHEMBL16395376 0.82 BACE1 (0.47) KDM4EHPGDHSD17B10MEN1KMT2A
SCHEMBL10496442 0.81 BACE1 (0.63) KDM4ESLC6A9HPGDHSD17B10MEN1
SCHEMBL17720805 0.81 PDE4D (0.47) KDM4EHPGDHSD17B10PTGDR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3012896-B1 NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND BIPHENYL GROUP-CONTAINING CARBONATE COMPOUND USED IN SAME UBE INDUSTRIES (JP) 2018-03-28 EP claimed
US-20160126593-A1 NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND BIPHENYL GROUP-CONTAINING CARBONATE COMPOUND USED IN SAME UBE INDUSTRIES, LTD. (JP) 2016-05-05 US claimed
US-20160126593-A1 NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND BIPHENYL GROUP-CONTAINING CARBONATE COMPOUND USED IN SAME UBE INDUSTRIES, LTD. (JP) 2016-05-05 US disclosed
US-20160126593-A1 NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND BIPHENYL GROUP-CONTAINING CARBONATE COMPOUND USED IN SAME UBE INDUSTRIES, LTD. (JP) 2016-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160126593-A1 NONAQUEOUS ELECTROLYTE SOLUTION, ELECTRICITY STORAGE DEVICE USING SAME, AND BIPHENYL GROUP-CONTAINING CARBONATE COMPOUND USED IN SAME BMI1, KCNN2, CACNA2D4 KDM4E 39/4885SLC6A9 181/4885EGFR 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.